Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Sundar Jagannath; Thierry Facon; Ashraf Z. Badros; Moshe Levy; Phillipe Moreau; Sosana Delimpasi; Maryana Simonova; Ivan Spicka; Iryrna Kriachok; Maria Gavriatopoulou; Halyna Pylypenko; Holger W. Auner; Xavier Leleu; Vadim Doronin; Ganna Usenko; Roman Hajek; Reuben Benjamin; Tuphan Kanti Dolai; Dinesh Kumar Sinha; Chris P. Venner; Mamta Garg; Mercedes Gironella  Mesa; Artur Jurczyszyn; Tadeusz Robak; Monica Galli; Craig Thomas Wallington-Beddoe; Atanas Radinoff; Galina Salogub; Don Stevens; Supratik Basu; Anna Marina Liberati; Hang Quach; Vesselina S. Goranova-Marinova; Jelena Sreten Bila; Eirini Katodritou; Andrew  DeCastro; Yi Chai; Dane R.  Van Domelen; Moran  Mishal; Ohad S.  Bentur; Jatin Shah; Sharon Shacham; Michael G. Kauffman; Sebastian Grosicki; Paul G. Richardson

doi:10.1182/blood-2021-146003

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Sundar Jagannath
, Thierry Facon
, Ashraf Z. Badros
, Moshe Levy
, Phillipe Moreau
, Sosana Delimpasi
, Maryana Simonova
, Ivan Spicka
, Iryrna Kriachok
, Maria Gavriatopoulou
, Halyna Pylypenko
, Holger W. Auner
, Xavier Leleu
, Vadim Doronin
, Ganna Usenko
, Roman Hajek
, Reuben Benjamin
, Tuphan Kanti Dolai
, Dinesh Kumar Sinha
, Chris P. Venner

Mamta Garg, Mercedes Gironella Mesa, Artur Jurczyszyn , Tadeusz Robak, Monica Galli, Craig Thomas Wallington-Beddoe, Atanas Radinoff, Galina Salogub, Don Stevens, Supratik Basu, Anna Marina Liberati, Hang Quach, Vesselina S. Goranova-Marinova , Jelena Sreten Bila, Eirini Katodritou , Andrew DeCastro, Yi Chai, Dane R. Van Domelen, Moran Mishal, Ohad S. Bentur, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Sebastian Grosicki, Paul G. Richardson

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Introduction: Treatment of multiple myeloma (MM) has greatly improved over the last two decades. However, most pts will relapse and develop refractory disease. Most anti-cancer regimens require dose modifications (interruption, reduction, or discontinuation) during the treatment course in order to optimize the therapeutic window; appropriate modifications improve tolerability while maintaining anti-cancer activity.

Original language	English
Article number	3793
Number of pages	4
Journal	Blood
Volume	138
Issue number	Supplement 1
DOIs	https://doi.org/10.1182/blood-2021-146003
Publication status	Published - Nov 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

myeloma
cancer
Bortezomib
Dexamethasone
Selinexor
XVd
Pts

Access to Document

10.1182/blood-2021-146003Licence: In Copyright

Cite this

Jagannath, S., Facon, T., Badros, A. Z., Levy, M., Moreau, P., Delimpasi, S., Simonova, M., Spicka, I., Kriachok, I., Gavriatopoulou , M., Pylypenko , H., Auner, H. W., Leleu, X., Doronin, V., Usenko, G., Hajek, R., Benjamin, R., Dolai, T. K., Sinha, D. K., ... Richardson, P. G. (2021). Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. Blood, 138(Supplement 1), Article 3793. https://doi.org/10.1182/blood-2021-146003

@article{5307f8a41f3141ff8369464f6de28a00,

title = "Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study",

abstract = "Introduction: Treatment of multiple myeloma (MM) has greatly improved over the last two decades. However, most pts will relapse and develop refractory disease. Most anti-cancer regimens require dose modifications (interruption, reduction, or discontinuation) during the treatment course in order to optimize the therapeutic window; appropriate modifications improve tolerability while maintaining anti-cancer activity.",

keywords = "myeloma, cancer, Bortezomib, Dexamethasone, Selinexor, XVd, Pts",

author = "Sundar Jagannath and Thierry Facon and Badros, \{Ashraf Z.\} and Moshe Levy and Phillipe Moreau and Sosana Delimpasi and Maryana Simonova and Ivan Spicka and Iryrna Kriachok and Maria Gavriatopoulou and Halyna Pylypenko and Auner, \{Holger W.\} and Xavier Leleu and Vadim Doronin and Ganna Usenko and Roman Hajek and Reuben Benjamin and Dolai, \{Tuphan Kanti\} and Sinha, \{Dinesh Kumar\} and Venner, \{Chris P.\} and Mamta Garg and Mesa, \{Mercedes Gironella\} and Artur Jurczyszyn and Tadeusz Robak and Monica Galli and Wallington-Beddoe, \{Craig Thomas\} and Atanas Radinoff and Galina Salogub and Don Stevens and Supratik Basu and Liberati, \{Anna Marina\} and Hang Quach and Goranova-Marinova, \{Vesselina S.\} and Bila, \{Jelena Sreten\} and Eirini Katodritou and Andrew DeCastro and Yi Chai and \{Van Domelen\}, \{Dane R.\} and Moran Mishal and Bentur, \{Ohad S.\} and Jatin Shah and Sharon Shacham and Kauffman, \{Michael G.\} and Sebastian Grosicki and Richardson, \{Paul G.\}",

year = "2021",

month = nov,

doi = "10.1182/blood-2021-146003",

language = "English",

volume = "138",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "Supplement 1",

}

Jagannath, S, Facon, T, Badros, AZ, Levy, M, Moreau, P, Delimpasi, S, Simonova, M, Spicka, I, Kriachok, I, Gavriatopoulou , M, Pylypenko , H, Auner, HW, Leleu, X, Doronin, V, Usenko, G, Hajek, R, Benjamin, R, Dolai, TK, Sinha, DK, Venner, CP, Garg, M, Mesa, MG, Jurczyszyn , A, Robak, T, Galli, M, Wallington-Beddoe, CT, Radinoff, A, Salogub, G, Stevens, D, Basu, S, Liberati, AM, Quach, H, Goranova-Marinova , VS, Bila, JS, Katodritou , E, DeCastro, A, Chai, Y, Van Domelen, DR, Mishal, M, Bentur, OS, Shah, J, Shacham, S, Kauffman, MG, Grosicki, S & Richardson, PG 2021, 'Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study', Blood, vol. 138, no. Supplement 1, 3793. https://doi.org/10.1182/blood-2021-146003

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. / Jagannath, Sundar; Facon, Thierry; Badros, Ashraf Z. et al.
In: Blood, Vol. 138, No. Supplement 1, 3793, 11.2021.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

AU - Jagannath, Sundar

AU - Facon, Thierry

AU - Badros, Ashraf Z.

AU - Levy, Moshe

AU - Moreau, Phillipe

AU - Delimpasi, Sosana

AU - Simonova, Maryana

AU - Spicka, Ivan

AU - Kriachok, Iryrna

AU - Gavriatopoulou , Maria

AU - Pylypenko , Halyna

AU - Auner, Holger W.

AU - Leleu, Xavier

AU - Doronin, Vadim

AU - Usenko, Ganna

AU - Hajek, Roman

AU - Benjamin, Reuben

AU - Dolai, Tuphan Kanti

AU - Sinha, Dinesh Kumar

AU - Venner, Chris P.

AU - Garg, Mamta

AU - Mesa, Mercedes Gironella

AU - Jurczyszyn , Artur

AU - Robak, Tadeusz

AU - Galli, Monica

AU - Wallington-Beddoe, Craig Thomas

AU - Radinoff, Atanas

AU - Salogub, Galina

AU - Stevens, Don

AU - Basu, Supratik

AU - Liberati, Anna Marina

AU - Quach, Hang

AU - Goranova-Marinova , Vesselina S.

AU - Bila, Jelena Sreten

AU - Katodritou , Eirini

AU - DeCastro, Andrew

AU - Chai, Yi

AU - Van Domelen, Dane R.

AU - Mishal, Moran

AU - Bentur, Ohad S.

AU - Shah, Jatin

AU - Shacham, Sharon

AU - Kauffman, Michael G.

AU - Grosicki, Sebastian

AU - Richardson, Paul G.

PY - 2021/11

Y1 - 2021/11

N2 - Introduction: Treatment of multiple myeloma (MM) has greatly improved over the last two decades. However, most pts will relapse and develop refractory disease. Most anti-cancer regimens require dose modifications (interruption, reduction, or discontinuation) during the treatment course in order to optimize the therapeutic window; appropriate modifications improve tolerability while maintaining anti-cancer activity.

AB - Introduction: Treatment of multiple myeloma (MM) has greatly improved over the last two decades. However, most pts will relapse and develop refractory disease. Most anti-cancer regimens require dose modifications (interruption, reduction, or discontinuation) during the treatment course in order to optimize the therapeutic window; appropriate modifications improve tolerability while maintaining anti-cancer activity.

KW - myeloma

KW - cancer

KW - Bortezomib

KW - Dexamethasone

KW - Selinexor

KW - XVd

KW - Pts

U2 - 10.1182/blood-2021-146003

DO - 10.1182/blood-2021-146003

M3 - Meeting Abstract

SN - 0006-4971

VL - 138

JO - Blood

JF - Blood

IS - Supplement 1

M1 - 3793

ER -

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this